New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3): Draft New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3)”
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 17, 2021
September 17, 2021
fa17132a-ca0a-4f0c-8b68-5b45a40f4059
Related Documents
Drug Master Files Guidance for Industry
Guidance DocumentNovember 15, 2019Center for Drug Evaluation and Research
Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry
Guidance DocumentSeptember 18, 2023Center for Drug Evaluation and Research
Nonproprietary Naming of Biological Products: Update Guidance for Industry
Guidance DocumentMarch 8, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox